{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.3.4 Criteria for Responders Who Relapse', 'If subjects met the response criteria at Week 24 of HZNP-TEP-301 but subsequently experience', 'a disease relapse during the 48-week Follow-Up Period of the lead-in study, they will have the', 'option to enter this open-label extension study (HZNP-TEP-302) and receive 8 infusions of', 'teprotumumab. The criteria to determine relapse is the following:', 'Increase in proptosis of > 2 mm in the study eye since Week 24 of HZNP-TEP-301, or', 'An increase in CAS of > 2 points since Week 24 with an absolute CAS of > 4 in the', 'study eye following Week 24 of HZNP-TEP-301', 'In addition to one of the bullet points above, the Investigator should also consider the', \"subject's symptomology to ensure a relapse has occurred (e.g., new onset of double\", 'vision).', '9.3.5', 'Replacement Policy', '9.3.5.1 Subjects', 'No subject prematurely discontinued from the study for any reason will be replaced.', '9.3.5.2 Centers', 'A center may be closed and/or replaced for the following administrative reasons:', 'Poor protocol adherence.', '9.4', 'Treatments', '9.4.1 Treatments Administered', 'All study drug dosing will be performed at the clinic under the supervision of clinic staff.', 'Subjects will receive 8 infusions of teprotumumab (10 mg/kg on Day 1 followed by 20 mg/kg', 'q3W for the remaining infusions) in an open-label fashion.', 'The infusion rate may be reduced and the dose may be interrupted or held based on tolerability', '(see Section 9.4.6.3.2 for details). The first and second infusions will be administered over', 'approximately 90 minutes (but not less than 80 minutes). Subsequent infusions will be', 'administered over approximately 60 minutes (but not less than 50 minutes), providing there are', 'no significant infusion-associated events.', '9.4.2 Identity of Investigational Product', 'Teprotumumab (HZN-001) is a fully human anti-IGF-1R mAb. The physiochemical properties', 'were previously presented in Section 7.1.3.1. Teprotumumab will be provided in single-dose', '20 mL glass vials as a freeze-dried powder containing, in addition to the drug substance,', '20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose, and 0.01% polysorbate 20 (w/w).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 75 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be', 'reconstituted with 10 mL of water for injection. The resulting solution has an approximate', 'concentration of 50 mg/mL teprotumumab. The reconstituted teprotumumab solution must be', 'further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration (see', 'Section 9.4.6.3 for details).', '9.4.3 Labeling', 'Study drug packaging will be in compliance with Sponsor/CRO standard procedures and will', 'meet all local requirements.', 'Upon arrival of investigational products at the site, the investigational pharmacist or site', 'personnel not assigned to the study should check them for damage and verify proper identity,', 'quantity, integrity of seals, and temperature conditions, and report any deviations or product', 'complaints to the monitor/Sponsor upon discovery.', '9.4.4 Storage', 'Recommended storage conditions for the freeze-dried teprotumumab drug product are between', '2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F), protected from light. Storage at ambient temperature of the', 'reconstituted teprotumumab solution should be limited to 4 hours. For batch-specific information', 'on shelf-life, see the packaging.', 'The IV infusion should be administered at room temperature (20\u00b0C to 24\u00b0C [68\u00b0F to 75\u00b0F]). The', 'diluted product should be used within 4 hours of preparation. However, if not used within', '4 hours, and if dilution has taken place under controlled and validated aseptic conditions, the', 'infusion solution can be stored for up to 24 hours at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). An', 'Investigational Pharmacy Manual will be provided to all sites and further describe these', 'processes in detail.', 'At the clinic, all study medications must be stored in a secure area with limited access, and a', 'daily temperature log of the drug storage area will be maintained every working day; deviations', 'from the specified temperature range will be reported as protocol deviations.', '9.4.5 Drug Accountability', 'The Principal Investigator at each site is responsible for the control of all study medication and', 'delegating infusion bag preparation and drug accountability responsibilities to a pharmacist (or', 'designee in accordance with institutional policies and local regulations), who must maintain', 'adequate records of the receipt and disposition of all study medication shipped to the study', 'center. Records will include receipt dates, condition at time of receipt, quantities received,', 'quantities dispensed, quantities returned or destroyed, and the identification numbers of the', 'subjects who received study medication.', 'As permitted by site policy, all empty, partially empty, and full vials of study drug must be', 'retained by the study center under locked storage until drug accountability has been completed.', 'Periodically throughout the study and at the conclusion of the study, inventory checks and', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 76 of 118']\n\n###\n\n", "completion": "END"}